ALS

PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland

Retrieved on: 
Monday, March 11, 2024

PolTREG was the first company in the world to administer T-reg therapies to patients, and the first to start receiving revenues from its lead product under a hospital exemption valid in Poland.

Key Points: 
  • PolTREG was the first company in the world to administer T-reg therapies to patients, and the first to start receiving revenues from its lead product under a hospital exemption valid in Poland.
  • Its manufacturing facility is one of Europe’s largest and most advanced, boasting over 2,100 sqm of laboratory space, including 15 production lines.
  • PolTREG has the option to substantially expand the facility to accommodate manufacturing of next-generation engineered therapies and cell therapies from future partners.
  • “This certification is an important recognition of PolTREG’s leading capabilities in manufacturing cellular therapies, a highly sophisticated process that requires deep experience to master,” said Prof. Piotr Trzonkowski, Chief Executive Officer of PolTREG.

AMLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Amylyx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Sunday, March 10, 2024

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/AMLX .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/AMLX .
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 9, 2024

The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.

Key Points: 
  • The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.
  • The Company offers its services through a mobile application and website, while also providing software-as-a-service solutions to retailers.
  • In addition, the complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program

Retrieved on: 
Friday, March 8, 2024

As part of the collaboration, the DoD TBIPHRP Award will fund Roskamp to undertake preclinical development in their well characterized TBI models using Biosplice’s DYRK inhibitors.

Key Points: 
  • As part of the collaboration, the DoD TBIPHRP Award will fund Roskamp to undertake preclinical development in their well characterized TBI models using Biosplice’s DYRK inhibitors.
  • The data from this collaboration are anticipated to inform the development of Biosplice’s DYRK inhibitor class in the treatment of degenerative neurological conditions, including various tauopathies.
  • This collaboration with Roskamp will help accelerate the development of our novel neurology therapies, ranging from TBI to ALS to Alzheimer’s disease.”
    This award builds upon more than four years of scientific collaboration between Roskamp and Biosplice.
  • Previous research conducted by Roskamp has demonstrated efficacy in TBI animal models with Biosplice’s first-generation DYRK inhibitors.

Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Retrieved on: 
Friday, March 8, 2024

BOSTON, March 08, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) for securities law violations.

Key Points: 
  • BOSTON, March 08, 2024 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) for securities law violations.
  • Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses.
  • Investors should contact Block & Leviton to learn more.
  • Block & Leviton is widely regarded as one of the leading securities class action firms in the country.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX

Retrieved on: 
Thursday, March 7, 2024

WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Amylyx class action, go to https://rosenlegal.com/submit-form/?case_id=22470 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Amylyx Pharmaceuticals Class Action: Johnson Fistel Encourages Amylyx Investors to Seek Counsel Before Lead Plaintiff Class Action Deadline

Retrieved on: 
Thursday, March 7, 2024

SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX).

Key Points: 
  • SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX).
  • The class action is on behalf of shareholders who purchased or otherwise acquired securities between November 11, 2022 to November 8, 2023, both dates inclusive (the “Class Period”).
  • Investors are hereby notified that they have until April 9, 2024, to move the Court to serve as lead plaintiff in this action.
  • An investor's ability to share any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Clene to Present at the 36th Annual ROTH Conference

Retrieved on: 
Thursday, March 7, 2024

SALT LAKE CITY, March 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the 36th Annual ROTH Conference being held March 18-19, 2024.

Key Points: 
  • SALT LAKE CITY, March 07, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the 36th Annual ROTH Conference being held March 18-19, 2024.
  • Location: The Ritz Carlton Laguna Niguel in Dana Point, California
    A webcast of the presentation will be available on the “ Events ” section of the Clene website.
  • Alternatively, one can register online to view the webcast here: https://wsw.com/webcast/roth48/clene/1959711 .

North Bay Resources Announces Assays from Murex Copper Project up to 3.12% Cu, 60.3g/t Au, 141g/t Ag, and 8.11% Zn

Retrieved on: 
Wednesday, March 6, 2024

SKIPPACK, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- North Bay Resources Inc. (the “Company” or “North Bay”) (OTC: NBRI) is pleased to announce previously unreleased assays (with the exception of sample #H619241) at its wholly owned Murex Copper Project (formerly Mt.

Key Points: 
  • SKIPPACK, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- North Bay Resources Inc. (the “Company” or “North Bay”) (OTC: NBRI) is pleased to announce previously unreleased assays (with the exception of sample #H619241) at its wholly owned Murex Copper Project (formerly Mt.
  • Fall 2023 Exploration consisted of geochemical and geological mapping in the North of the property, yielding the following assays:
    Fall 2023 Exploration consisted of 6 rock chip samples covering the Lupus and Lakeview Zones.
  • Rock chip sampling consisted of geochemical analysis at ALS Chemex Labs, North Vancouver, B.C.
  • The Company has completed exploration at the Copper Bell Zone where Summer 2023 Exploration resulted in assays up to 14.7% copper (see Press Release dated February 16th, 2024).